NewLimit, founded by the CEO of CEX, has completed a $130 million Series B financing round, led by Kleiner Perkins.

GateUser-6433627c · 2025-05-06T16:24:05+00:00

The anti-aging company NewLimit has completed a $130 million Series B funding round, dedicated to gene programming to extend healthy lifespan. The company has discovered three prototype drugs that can reprogram liver cells and has made significant progress. Experiments show that regenerative therapy can restore youthful characteristics to aging liver cells, but human trials will still take several years.

GateUser-6433627c

2025-05-06 16:24:05

Abstract generation in progress

On May 6, anti-aging company NewLimit, founded by CEX CEO Brian Armstrong, announced the completion of a $130 million Series B funding round, led by Kleiner Perkins, with participation from Nat Friedman, Daniel Gross, and Khosla Ventures. NewLimit aims to extend people’s healthy lifespan by gene programming cells. Founded four years ago by Brian Armstrong, former GV partner Blake Bryers, and stem cell professor Jacob Kimmel, the company claims to have made significant progress in developing treatments to restore the youthful characteristics of aging cells. The company has identified three prototype drugs that can reprogram liver cells. Bryers stated that laboratory experiments at NewLimit indicate that this regenerative therapy can restore the ability of cells to process fats and alcohol. The company measures its progress by comparing the response of young and old cells to these substances. Liver cells from older individuals that have undergone NewLeaf epigenetic reprogramming behave more like young cells. Although the early results are promising, NewLimit is still several years away from starting human trials.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.